28 September 2010
Director's Share Transfer
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that David Davies, Director of Product Development, has today transferred 160,239 ordinary shares in the Company into his Hargreaves Lansdown Vantage SIPP account for no consideration.
There is no change in the beneficial ownership of these ordinary shares, and Mr Davies's holding in ordinary shares in the Company, as defined by the AIM Rules, remains unchanged as a result of the transfer at 532,572 ordinary shares, representing 0.79% of the Company's share capital.
For further information please contact:
Nomura Code Securities Limited
Phil Walker / Giles Balleny
Tel: +44 (0) 20 7776 1200
For media enquiries please contact:
Buchanan Communications Limited
Mark Court / Fiona Henson
Tel: +44 (0) 20 7466 5000
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.